Sep 17, 2022 / 10:30PM GMT
Mark Wilterding - Edwards Lifesciences Corporation - VP of IR
Here in Boston, and we appreciate you all spending time with us as well as for those of you online. We've got a great session, I think, lined up this evening. And it's really the reflection of a lot of great news that we had over the course of this week. On Monday, the FDA-approved SAPIEN 3 Ultra with RESILIA. On Thursday, we got FDA approval for PASCAL to treat DMR patients here in the U.S.
And today, we presented, I think, some pretty compelling data at the conference itself. So that's going to be kind of the flow of the evening session.
I'll start by calling your attention to the forward-looking statement. We will, as we do, and these events have a tendency to make forward-looking statements. I would just call your attention to this. It's also available on our website, so please familiarize yourself with it. This is the agenda itself. So I mentioned it's about an hour session, we're going to break it up into 2 parts.
The first portion of the session, you can see we've gathered some of our TMTT leaders here on
Edwards Lifesciences Corp Investor Update at TCT Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers